Influence of protease inhibitor therapy on lipoprotein metabolism

Journal of Internal Medicine

Volumn 246, Issue 6, 1999, Pages 567-575

  Berthold, Heiner K ^a   Parhofer, K G ^b   Ritter, M M ^b   Addo, M ^b   Wasmuth, J C ^b   Schliefer, K ^b   Spengler, U ^b   Rockstroh, J K ^b  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

Adverse effects; Chemically induced hyperlipoproteinemia; Highly active antiretroviral therapy; Hypercholesterolemia; Hypertriglyceridemia; Protease inhibitors

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CD4 LYMPHOCYTE COUNT; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; INDINAVIR; LIPOPROTEINS; MALE; MIDDLE AGED; NELFINAVIR; PROSPECTIVE STUDIES; RITONAVIR; VIRAL LOAD;

EID: 0033428794     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00615.x     Document Type: Article

References (26)

1. 1 Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
2. 2 Carpenter CC, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA panel. JAMA 1999; 280: 78-86.
3. 3 BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-92.
4. 4 Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
5. 5 Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53.
6. 6 Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-3.
7. 7 Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
8. 8 Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (RR-17): 1-19.
9. 9 Mailly F, Davignon J, Nestruck AC. Analytical isoelectric focusing with immobilized pH gradients of human apolipoprotein E from very low density lipoproteins and total plasma. J Lipid Res 1990; 31: 149-55.
10. 10 National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-445.
11. 11 Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
12. 12 Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993; 37: 1207-13.
13. 1 3 Shor-Posner G, Basit A, Lu Y et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94: 515-9.
14. 14 Hellerstein MK, Grunfeld C, Wu K et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 76: 559-65.
15. 15 Fernandez Miranda C, Pulido F, Carrillo JL et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998; 274: 63-70.
16. 16 Pirich C, Efthimiou Y, O'Grady J, Zielinski C, Sinzinger H. Apolipoprotein A and biological half-life of prostaglandin 12 in HIV-1 infection. Thromb Res 1996; 81: 213-8.
17. 17 Kereveur A, Cambillau M, Kazatchkine M, Moatti N. Anomalies lipoproteiniques au cours de l'infection par le VIH [Lipoprotein anomalies in HIV infections]. Ann Med Interne Paris 1996; 147: 333-43.
18. 18 Constans J. Pellegrin JL, Peuchant E et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416-20.
19. 19 Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Aquir Immune Defic Syndr 1994; 7: 1149-56.
20. 20 Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-52.
21. 21 Jenkins PG, Harper RW, Nestel PJ. Severity of coronary atherosclerosis related to lipoprotein concentrations. Br Med J 1978; 2: 388-91.
22. 22 Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM Experience). Am J Cardiol 1992; 70: 733-7.
23. 23 Campos H, Roederer GO, Lussier-Cacan S, Davignon J, Krauss RM. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 1043-8.
24. 24 Reaven GM. Role of insulin resistance in human disease. Diabetes 1988: 37: 1595-607.
25. 25 Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy. hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F8.
26. 26 Segerer S, Bogner JR, Walli R, Loch O, Goebel F-D. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27: 77-81.